Creative Medical Technology Holdings developing ovary regeneration technology

Creative Medical Technology has filed a patent application for a type of stem cell technology that can regenerate failing ovaries, a method that can help women suffering from premature ovarian failure.

Creative Medical, a biotechnology company based in Phoenix, already manufactures an erectile dysfunction product that uses a patient’s own stem cells.

The company's ovary regeneration technology uses cells from a patient’s bone marrow that generate new blood vessels and creates a treatment that replaces scar tissue, the company said in a statement. The technology is targeted for women who experience accelerated menopause.

According to Creative Medical, one in 100 women under the age of 40 are affected by premature ovarian failure. There currently is no other effective treatment for the condition.

"Currently we are focusing on premature ovarian failure as an initial clinical indication," said Timothy Warbington, president and CEO of Creative Medical, in a statement. "Initial success in this indication will allow us to address aspects of the wider infertility market, which is estimated to reach over $20 billion annually."

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.